Middle East Tech Today
SEE OTHER BRANDS

The best science and technology news from the Middle East

Middle East Tech Today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East Tech Today.

Press releases published on April 24, 2025

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host  Conference Call and Webcast on May 1, 2025

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the first quarter ended March …

Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference

Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference

WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today …

Gladly Garners “Overall Customer Experience Solution of the Year” In 2025 RetailTech Breakthrough Awards Program

Gladly Garners “Overall Customer Experience Solution of the Year” In 2025 RetailTech Breakthrough Awards Program

SAN FRANCISCO, April 24, 2025 (GLOBE NEWSWIRE) -- RetailTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout retail technology companies, products, and services around the globe, today announced …

Pacvue Receives “Overall Digital Commerce Platform of the Year” In 2025 RetailTech Breakthrough Awards Program

Pacvue Receives “Overall Digital Commerce Platform of the Year” In 2025 RetailTech Breakthrough Awards Program

LOS ANGELES, April 24, 2025 (GLOBE NEWSWIRE) -- Pacvue, the leading commerce acceleration platform that integrates retail media, commerce management and measurement, today announced it is the recipient of “Overall Digital Commerce Platform of the Year” in …

Northstrive Biosciences Announces Positive FDA Response Supporting A Submission of IND for a Phase 2 Clinical Trial for EL-22 in Combination with GLP-1 Receptor Agonist for Obesity Treatment

Northstrive Biosciences Announces Positive FDA Response Supporting A Submission of IND for a Phase 2 Clinical Trial for EL-22 in Combination with GLP-1 Receptor Agonist for Obesity Treatment

Northstrive Biosciences received preliminary meeting responses from the FDA regarding Northstrive’s nonclinical studies and clinical development plans for EL-22, administered in combination with GLP-1 receptor agonists. Northstrive believes the FDA …

SpyGlass Pharma Presents 18-Month Data Demonstrating Compelling Visual Acuity Results with Their IOL-mounted Innovative Drug Delivery Platform

SpyGlass Pharma Presents 18-Month Data Demonstrating Compelling Visual Acuity Results with Their IOL-mounted Innovative Drug Delivery Platform

All patients achieved 20/30 or better best corrected distance visual acuity (BCDVA) Significant IOP reduction at 18 months was also demonstrated with 100% of patients off all topical IOP-lowering medication ALISO VIEJO, Calif., April 24, 2025 (GLOBE …

NephroDI Therapeutics’ Founder and CMO Jeff M. Sands, M.D. Receives the  2025 Robert W. Berliner Award for Excellence in Renal Physiology

NephroDI Therapeutics’ Founder and CMO Jeff M. Sands, M.D. Receives the 2025 Robert W. Berliner Award for Excellence in Renal Physiology

April 25, 2025, Seattle, WA – NephroDI Therapeutics (NephroDI), a pharmaceutical company focusing on kidney disorders, announces that its Founder and CMO, Jeff M. Sands, M.D., is the recipient of the 2025 Robert W. Berliner Award for Excellence in Renal …

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

– Expands Development Portfolio with Introduction of a Novel Program Targeting PSC – – Confirms Highly Specific Allosteric ACLY Inhibitor Shown to Reduce Liver Injury, Inflammation and Fibrosis Across Multiple PSC-Relevant Pre-Clinical Models – – …

ClearScale Signs New Strategic Collaboration Agreement with AWS to Empower Small and Medium-Sized Businesses to Accelerate Value in the Cloud

ClearScale Signs New Strategic Collaboration Agreement with AWS to Empower Small and Medium-Sized Businesses to Accelerate Value in the Cloud

SAN FRANCISCO, April 24, 2025 (GLOBE NEWSWIRE) -- ClearScale, an AWS Premier Tier Services Partner and cloud consulting company, announced today it has signed a multi-year strategic collaboration agreement (SCA) with Amazon Web Services (AWS) as part of …

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today …

Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025

Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its first …

Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and European countries in 2024-2025 Cocrystal Pharma’s pan-viral protease inhibitor CDI-988 shows superior broad- …

Prebid.org Debuts New Analytics Dashboard, Prebid Insights

Prebid.org Debuts New Analytics Dashboard, Prebid Insights

NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Prebid.org, the organization that oversees open source Prebid programmatic advertising solutions, today announced the launch of Prebid Insights, a new, publicly available analytics dashboard designed to provide …

Carterra Announces its 2025 Symposia Series on Speeding Drug Discovery with AI/ML and Other New Technologies

Carterra Announces its 2025 Symposia Series on Speeding Drug Discovery with AI/ML and Other New Technologies

Presentations will be delivered by experts from a wide variety of leading research groups including Pfizer, GSK, and Bio-Techne, along with co-hosts IPA, ACROBiosystems, and Curia. SALT LAKE CITY, April 24, 2025 (GLOBE NEWSWIRE) -- Carterra Inc., the world …

Indicium Unveils IndiMesh, an AI-Enabled Software and Services Framework Created to Help Large Enterprises Build, Scale and Sustain AI and Data Solutions

Indicium Unveils IndiMesh, an AI-Enabled Software and Services Framework Created to Help Large Enterprises Build, Scale and Sustain AI and Data Solutions

NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Indicium, the AI and data consultancy, announces IndiMesh, an AI-enabled framework that transforms how enterprises build, scale and sustain data and AI solutions. IndiMesh combines a structured training model, …

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025

IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer …

Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the …

Cronos Group Inc. to Hold 2025 First Quarter Earnings Conference Call on May 8, 2025

Cronos Group Inc. to Hold 2025 First Quarter Earnings Conference Call on May 8, 2025

TORONTO, April 24, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2025 first quarter earnings conference call on Thursday, May 8, 2025 at 8:30 a.m. ET. Cronos’ senior management team will …

Performance Unlocked: AdOmni and LiveRamp Bring New Targeting and Attribution to CTV, OLV, and DOOH

Performance Unlocked: AdOmni and LiveRamp Bring New Targeting and Attribution to CTV, OLV, and DOOH

LAS VEGAS and SAN FRANCISCO, April 24, 2025 (GLOBE NEWSWIRE) -- Marketers have long struggled to measure the business impact of CTV, OLV, and DOOH—keeping these high-reach channels siloed from performance strategies. Today, AdOmni, the AI-powered video- …

Microchip Unveils New High-Density Power Module for AI at the Edge Applications

Microchip Unveils New High-Density Power Module for AI at the Edge Applications

CHANDLER, Ariz., April 24, 2025 (GLOBE NEWSWIRE) -- AI at the edge is driving increased integration and power consumption, requiring advanced power management solutions for industrial automation and data center applications. Microchip Technology (Nasdaq: …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service